FDA Brief

Warning letters Food

FDA warning letter to

Orphic Nutrition

High riskIssued Apr 13, 2021Posted Apr 27, 2021Office of Human and Animal Food Operations –West Division 5

FDA warned Orphic Nutrition that its supplement capsules and gummies are unapproved new drugs because website claims say they treat diseases.

What happened

FDA reviewed Orphic Nutrition's website and Amazon storefront in March 2021 and found it took orders for seven supplement products. FDA cited many product claims that the supplements treat or prevent diseases, including diabetes, high blood pressure, cancer, colds/flu, and joint disease. FDA therefore calls the products drugs, unapproved new drugs, and—for six products—misbranded for lacking adequate directions for use.

What FDA found

  1. The website and Amazon listings claim the supplements cure, mitigate, treat, or prevent diseases such as diabetes, high blood pressure, cancer, colds, flu, and arthritis, which makes them drugs under the law.

    FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]
  2. The products are 'new drugs'—products that need FDA approval before sale—because they are not generally recognized as safe and effective for those uses and FDA has not approved them.

    FD&C Act sections 201(p), 301(d), 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]
  3. Six products are misbranded—improperly labeled—because they lack adequate directions for a layperson to use them safely for the diseases they claim to treat.

    FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. Shipping or selling these misbranded drugs in interstate commerce violates the Act.

    FD&C Act section 301(a) [21 U.S.C. 331(a)]

What FDA wants

FDA asks Orphic Nutrition to notify it in writing within 15 working days of receipt of the letter about specific steps taken to correct the violations, how recurrence will be prevented, and to include supporting documents; if it cannot finish, it must explain why and give a completion date.

Who should pay attention

  • supplement brands selling online or on Amazon
  • companies making disease-treatment claims for dietary supplements
  • quality and regulatory teams reviewing website and marketplace claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk